A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethality

Bijina Balakrishnan, Jan Verheijen, Arielle Lupo, Kimiyo Raymond, Coleman Turgeon, Yueqin Yang, Kandis L. Carter, Kevin J. Whitehead, Tamas Kozicz, Eva Morava-Kozicz, Kent Lai

Research output: Contribution to journalArticle

Abstract

Patients with phosphoglucomutase (PGM1) deficiency, a congenital disorder of glycosylation (CDG) suffer from multiple disease phenotypes. Midline cleft defects are present at birth. Overtime, additional clinical phenotypes, which include severe hypoglycemia, hepatopathy, growth retardation, hormonal deficiencies, hemostatic anomalies, frequently lethal, early-onset of dilated cardiomyopathy and myopathy emerge, reflecting the central roles of the enzyme in (glycogen) metabolism and glycosylation. To delineate the pathophysiology of the tissue-specific disease phenotypes, we constructed a constitutive Pgm2 (mouse ortholog of human PGM1)-knockout (KO) mouse model using CRISPR-Cas9 technology. After multiple crosses between heterozygous parents, we were unable to identify homozygous life births in 78 newborn pups (P = 1.59897E-06), suggesting an embryonic lethality phenotype in the homozygotes. Ultrasound studies of the course of pregnancy confirmed Pgm2-deficient pups succumb before E9.5. Oral galactose supplementation (9 mg/mL drinking water) did not rescue the lethality. Biochemical studies of tissues and skin fibroblasts harvested from heterozygous animals confirmed reduced Pgm2 enzyme activity and abundance, but no change in glycogen content. However, glycomics analyses in serum revealed an abnormal glycosylation pattern in the Pgm2+/− animals, similar to that seen in PGM1-CDG.

Original languageEnglish (US)
JournalJournal of inherited metabolic disease
DOIs
StatePublished - Jan 1 2019

Fingerprint

Phosphoglucomutase
Glycosylation
Congenital Disorders of Glycosylation
Phenotype
Glycogen
Clustered Regularly Interspaced Short Palindromic Repeats
Parturition
Glycomics
Homozygote
Dilated Cardiomyopathy
Muscular Diseases
Hemostatics
Enzymes
Galactose
Hypoglycemia
Knockout Mice
Drinking Water
Fibroblasts
Parents
Newborn Infant

Keywords

  • aberrant N-linked glycosylation
  • congenital disorders of glycosylation
  • embryonic lethality
  • galactose supplementation
  • inborn errors of metabolism
  • phosphoglucomutase 1 deficiency

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethality. / Balakrishnan, Bijina; Verheijen, Jan; Lupo, Arielle; Raymond, Kimiyo; Turgeon, Coleman; Yang, Yueqin; Carter, Kandis L.; Whitehead, Kevin J.; Kozicz, Tamas; Morava-Kozicz, Eva; Lai, Kent.

In: Journal of inherited metabolic disease, 01.01.2019.

Research output: Contribution to journalArticle

Balakrishnan, Bijina ; Verheijen, Jan ; Lupo, Arielle ; Raymond, Kimiyo ; Turgeon, Coleman ; Yang, Yueqin ; Carter, Kandis L. ; Whitehead, Kevin J. ; Kozicz, Tamas ; Morava-Kozicz, Eva ; Lai, Kent. / A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethality. In: Journal of inherited metabolic disease. 2019.
@article{0a6d318997b04ebdb81bc08a81baaf02,
title = "A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethality",
abstract = "Patients with phosphoglucomutase (PGM1) deficiency, a congenital disorder of glycosylation (CDG) suffer from multiple disease phenotypes. Midline cleft defects are present at birth. Overtime, additional clinical phenotypes, which include severe hypoglycemia, hepatopathy, growth retardation, hormonal deficiencies, hemostatic anomalies, frequently lethal, early-onset of dilated cardiomyopathy and myopathy emerge, reflecting the central roles of the enzyme in (glycogen) metabolism and glycosylation. To delineate the pathophysiology of the tissue-specific disease phenotypes, we constructed a constitutive Pgm2 (mouse ortholog of human PGM1)-knockout (KO) mouse model using CRISPR-Cas9 technology. After multiple crosses between heterozygous parents, we were unable to identify homozygous life births in 78 newborn pups (P = 1.59897E-06), suggesting an embryonic lethality phenotype in the homozygotes. Ultrasound studies of the course of pregnancy confirmed Pgm2-deficient pups succumb before E9.5. Oral galactose supplementation (9 mg/mL drinking water) did not rescue the lethality. Biochemical studies of tissues and skin fibroblasts harvested from heterozygous animals confirmed reduced Pgm2 enzyme activity and abundance, but no change in glycogen content. However, glycomics analyses in serum revealed an abnormal glycosylation pattern in the Pgm2+/− animals, similar to that seen in PGM1-CDG.",
keywords = "aberrant N-linked glycosylation, congenital disorders of glycosylation, embryonic lethality, galactose supplementation, inborn errors of metabolism, phosphoglucomutase 1 deficiency",
author = "Bijina Balakrishnan and Jan Verheijen and Arielle Lupo and Kimiyo Raymond and Coleman Turgeon and Yueqin Yang and Carter, {Kandis L.} and Whitehead, {Kevin J.} and Tamas Kozicz and Eva Morava-Kozicz and Kent Lai",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jimd.12110",
language = "English (US)",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethality

AU - Balakrishnan, Bijina

AU - Verheijen, Jan

AU - Lupo, Arielle

AU - Raymond, Kimiyo

AU - Turgeon, Coleman

AU - Yang, Yueqin

AU - Carter, Kandis L.

AU - Whitehead, Kevin J.

AU - Kozicz, Tamas

AU - Morava-Kozicz, Eva

AU - Lai, Kent

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients with phosphoglucomutase (PGM1) deficiency, a congenital disorder of glycosylation (CDG) suffer from multiple disease phenotypes. Midline cleft defects are present at birth. Overtime, additional clinical phenotypes, which include severe hypoglycemia, hepatopathy, growth retardation, hormonal deficiencies, hemostatic anomalies, frequently lethal, early-onset of dilated cardiomyopathy and myopathy emerge, reflecting the central roles of the enzyme in (glycogen) metabolism and glycosylation. To delineate the pathophysiology of the tissue-specific disease phenotypes, we constructed a constitutive Pgm2 (mouse ortholog of human PGM1)-knockout (KO) mouse model using CRISPR-Cas9 technology. After multiple crosses between heterozygous parents, we were unable to identify homozygous life births in 78 newborn pups (P = 1.59897E-06), suggesting an embryonic lethality phenotype in the homozygotes. Ultrasound studies of the course of pregnancy confirmed Pgm2-deficient pups succumb before E9.5. Oral galactose supplementation (9 mg/mL drinking water) did not rescue the lethality. Biochemical studies of tissues and skin fibroblasts harvested from heterozygous animals confirmed reduced Pgm2 enzyme activity and abundance, but no change in glycogen content. However, glycomics analyses in serum revealed an abnormal glycosylation pattern in the Pgm2+/− animals, similar to that seen in PGM1-CDG.

AB - Patients with phosphoglucomutase (PGM1) deficiency, a congenital disorder of glycosylation (CDG) suffer from multiple disease phenotypes. Midline cleft defects are present at birth. Overtime, additional clinical phenotypes, which include severe hypoglycemia, hepatopathy, growth retardation, hormonal deficiencies, hemostatic anomalies, frequently lethal, early-onset of dilated cardiomyopathy and myopathy emerge, reflecting the central roles of the enzyme in (glycogen) metabolism and glycosylation. To delineate the pathophysiology of the tissue-specific disease phenotypes, we constructed a constitutive Pgm2 (mouse ortholog of human PGM1)-knockout (KO) mouse model using CRISPR-Cas9 technology. After multiple crosses between heterozygous parents, we were unable to identify homozygous life births in 78 newborn pups (P = 1.59897E-06), suggesting an embryonic lethality phenotype in the homozygotes. Ultrasound studies of the course of pregnancy confirmed Pgm2-deficient pups succumb before E9.5. Oral galactose supplementation (9 mg/mL drinking water) did not rescue the lethality. Biochemical studies of tissues and skin fibroblasts harvested from heterozygous animals confirmed reduced Pgm2 enzyme activity and abundance, but no change in glycogen content. However, glycomics analyses in serum revealed an abnormal glycosylation pattern in the Pgm2+/− animals, similar to that seen in PGM1-CDG.

KW - aberrant N-linked glycosylation

KW - congenital disorders of glycosylation

KW - embryonic lethality

KW - galactose supplementation

KW - inborn errors of metabolism

KW - phosphoglucomutase 1 deficiency

UR - http://www.scopus.com/inward/record.url?scp=85067863926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067863926&partnerID=8YFLogxK

U2 - 10.1002/jimd.12110

DO - 10.1002/jimd.12110

M3 - Article

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

ER -